Clinical Trials on Dermatitis, Seborrheic

Total 3004 results

Eli Lilly and Company

Active, not recruiting

A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab (ADapt)

Atopic Dermatitis

United States
Dermavant Sciences, Inc.

Completed

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

Atopic Dermatitis

United States, Canada
AbbVie

Completed

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis (Heads Up)

Atopic Dermatitis

United States, Australia, Canada, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Malaysia, Netherlands, New Zealand, Norway, Poland, Singapore, Spain, Sweden, Taiwan, Ukraine, United Kingdom
Tianjin Hemay Pharmaceutical Co., Ltd

Completed

A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients

Atopic Dermatitis

China
Bayer

Completed

A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis (Damask)

Atopic Dermatitis

France, Czechia, Italy, Poland, United States, Germany, United Kingdom
RAPT Therapeutics, Inc.

Suspended

An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Shanghai Mabgeek Biotech.Co.Ltd

Active, not recruiting

A Study of MG-K10 in Subjects With Atopic Dermatitis

Atopic Dermatitis

China
CorEvitas

Enrolling by invitation

CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

Atopic Dermatitis

United States
Aclaris Therapeutics, Inc.

Completed

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

Atopic Dermatitis

United States
LEO Pharma

Completed

A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD

Atopic Dermatitis

Austria
Central Hospital, Nancy, France

Completed

Use of Complementary and Alternative Medicine in Children and Adults With Atopic Dermatitis

Atopic Dermatitis

France
Bristol-Myers Squibb

Completed

A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

Dermatitis, Atopic

Germany, Australia, Poland, Canada, Austria, United States, Spain
Northwestern University
Pfizer

Completed

Wearable Skin Sensors to Assess Nocturnal Scratch Behavior

Atopic Dermatitis

United States
Libbs Farmacêutica LTDA

Completed

Comparative Study:Topison (Mometasone Furoate) Versus Two Others Mometasone Furoates (LB2001)

Atopic Dermatitis

Brazil
AbbVie

Completed

Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Australia, Canada, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Malaysia, Netherlands, New Zealand, Norway, Poland, Singapore, Spain, Taiwan, Ukraine, United Kingdom
Aclaris Therapeutics, Inc.

Completed

Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

Atopic Dermatitis

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis

Eczema | Atopic Dermatitis

United States
OM Pharma SA

Terminated

Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD

Atopic Dermatitis

Germany, France, Poland, Netherlands
Pfizer

Active, not recruiting

A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

Atopic Dermatitis

India
Biosion, Inc.
Southern Star Research Pty Ltd.

Completed

Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis

Atopic Dermatitis

Australia
Dermavant Sciences, Inc.

Completed

Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Asana BioSciences

Completed

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

Atopic Dermatitis

United States, Germany, Canada
Bayer

Completed

Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis

Atopic Dermatitis

South Africa
Dermavant Sciences GmbH

Completed

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults

Atopic Dermatitis

United States, Canada
Eli Lilly and Company
Dermira, Inc.

Completed

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2)

Atopic Dermatitis

United States, Canada, Taiwan, Singapore, Germany, Bulgaria, Ukraine, Mexico
Reistone Biopharma Company Limited

Completed

A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

China
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)

Atopic Dermatitis

United States
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Atopic Dermatitis

United States, Canada, Czechia, Germany, Hungary, Poland, United Kingdom
Pfizer

Completed

Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis

Atopic Dermatitis

United States
Dermavant Sciences GmbH

Completed

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)

Atopic Dermatitis

United States, Canada
Noos S.r.l.

Completed

Effects of Lactobacillus Reuteri Plus Vitamin D3 in Children With Atopic Dermatitis

Atopic Dermatitis

Italy
AbbVie

Completed

A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Rising Up)

Atopic Dermatitis

Japan
Eli Lilly and Company
Dermira, Inc.

Completed

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis (ADore)

Atopic Dermatitis

United States, Canada, Australia, Poland
LEO Pharma

Completed

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) (ECZTRA 1)

Atopic Dermatitis

United States, Japan, France, Germany, Spain
Chang Gung Memorial Hospital
Ministry of Science and Technology, Taiwan

Completed

Comparison of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic® Ointment 0.1% in Treating Atopic Dermatitis

Atopic Dermatitis

Taiwan
Pfizer

Completed

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis (JADE MOA)

Atopic Dermatitis

United States, Canada
AbbVie

Active, not recruiting

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

Atopic Dermatitis

United States, Norway, Puerto Rico
Eli Lilly and Company
Dermira, Inc.

Completed

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)

Atopic Dermatitis

United States, Spain, Korea, Republic of, Australia, France, Canada, Estonia, Latvia, Lithuania, Poland
Hoth Therapeutics, Inc.
Novotech (Australia) Pty Limited

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

Australia
Eli Lilly and Company
Incyte Corporation

Terminated

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis (BREEZE-AD6)

Atopic Dermatitis

United States, Puerto Rico, Canada
LEO Pharma

Completed

Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis (ECZTRA 8)

Atopic Dermatitis

Japan
Eli Lilly and Company
Incyte Corporation

Completed

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis (BREEZE-AD5)

Atopic Dermatitis

United States, Puerto Rico, Canada
Johns Hopkins University
AD RescueWear

Withdrawn

Tencel vs. Standard Cotton Therapeutic Garments as an Adjunct Treatment for Moderate to Severe Atopic Dermatitis in Children

Atopic Dermatitis

United States
Akesobio Australia Pty Ltd

Completed

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Atopic Dermatitis

New Zealand, Australia
Pfizer

Completed

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis (JADE TEEN)

Atopic Dermatitis

Spain, United States, Taiwan, Germany, China, Hungary, Australia, Czechia, Japan, Latvia, Poland, United Kingdom, Mexico, Italy
Oneness Biotech Co., Ltd.

Completed

Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis

Atopic Dermatitis

Taiwan
Wake Forest University Health Sciences

Completed

Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis

Atopic Dermatitis

United States
MEDA Pharma GmbH & Co. KG

Completed

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States, Germany
Pfizer

Completed

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

Atopic Dermatitis

China, United States, Turkey, Australia, Canada, Israel
Shaperon

Completed

A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon)

Atopic Dermatitis

Korea, Republic of

3

Subscribe